Biosante Pharmaceuticals Aktie
68,50
EUR
-0,50
EUR
-0,72
%
79,39
USD
-1,08
USD
-1,34
%
Biosante Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Biosante Pharmaceuticals Aktie Analyse
| 16.10.17 | Biosante Pharmaceuticals Buy | Canaccord Adams | |
| 31.07.17 | Biosante Pharmaceuticals Buy | Canaccord Adams | |
| 24.05.16 | Biosante Pharmaceuticals Hold | Standpoint Research | |
| 13.11.15 | Biosante Pharmaceuticals Buy | Standpoint Research | |
| 28.09.15 | Biosante Pharmaceuticals Buy | ROTH Capital Partners, LLC | |
| 05.08.15 | Biosante Pharmaceuticals Outperform | Oppenheimer & Co. Inc. | |
| 04.08.15 | Biosante Pharmaceuticals Neutral | ROTH Capital Partners, LLC | |
| 31.07.15 | Biosante Pharmaceuticals Outperform | Oppenheimer & Co. Inc. | |
|
Werbung
|
|||
| 15.07.15 | Biosante Pharmaceuticals Neutral | ROTH Capital Partners, LLC | |
| 23.06.15 | Biosante Pharmaceuticals Outperform | Oppenheimer & Co. Inc. | |
| 18.05.15 | Biosante Pharmaceuticals Neutral | ROTH Capital Partners, LLC | |
| 06.05.15 | Biosante Pharmaceuticals Outperform | Oppenheimer & Co. Inc. | |
| 10.04.15 | Biosante Pharmaceuticals Neutral | ROTH Capital Partners, LLC | |
| 26.02.15 | Biosante Pharmaceuticals Buy | ROTH Capital Partners, LLC | |
| 18.02.15 | Biosante Pharmaceuticals Outperform | Oppenheimer & Co. Inc. | |
| 20.11.14 | Biosante Pharmaceuticals Buy | ROTH Capital Partners, LLC | |
Werbung
Werbung